Jump to main content
Jump to site search

Issue 9, 2019
Previous Article Next Article

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Author affiliations

Abstract

A graphical abstract is available for this content

Graphical abstract: A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Back to tab navigation

Article information


Submitted
16 Aug 2019
Accepted
16 Aug 2019
First published
30 Aug 2019

Med. Chem. Commun., 2019,10, 1509-1511
Article type
Editorial

A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

C. W. Murray, D. R. Newell and P. Angibaud, Med. Chem. Commun., 2019, 10, 1509
DOI: 10.1039/C9MD90044F

Search articles by author

Spotlight

Advertisements